1.7591
price up icon2.63%   0.0491
 
loading

Immuneering Corp Aktie (IMRX) Neueste Nachrichten

pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Immuneering Corp SEC 10-Q Report - TradingView

May 05, 2025
pulisher
May 05, 2025

Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan

May 05, 2025
pulisher
May 01, 2025

Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com

May 01, 2025
pulisher
May 01, 2025

What technical indicators reveal about IMRX stock - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 05, 2025

Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 28, 2025

Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 23, 2025

Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter

Mar 23, 2025
pulisher
Mar 23, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corp SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints Igor Matushansky as CMO - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints new Chief Medical Officer - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan

Mar 20, 2025
pulisher
Mar 05, 2025

Immuneering Slides As Insider Purchases Lose Another US$186k - Yahoo Finance

Mar 05, 2025
pulisher
Mar 03, 2025

Brokerages Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.20 - Armenian Reporter

Mar 03, 2025
pulisher
Mar 03, 2025

Immuneering Co. (NASDAQ:IMRX) Receives $12.20 Consensus PT from Analysts - Defense World

Mar 03, 2025
pulisher
Feb 28, 2025

Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday - Defense World

Feb 28, 2025
pulisher
Feb 14, 2025

Alkermes (NASDAQ:ALKS) & Immuneering (NASDAQ:IMRX) Head to Head Contrast - Armenian Reporter

Feb 14, 2025
pulisher
Feb 10, 2025

Needham & Company LLC Reaffirms "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat

Feb 10, 2025
pulisher
Feb 07, 2025

Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Immuneering and Regeneron partner on lung cancer trial - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Immuneering and Regeneron partner on lung cancer trial By Investing.com - Investing.com UK

Feb 06, 2025
pulisher
Feb 06, 2025

Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World

Feb 06, 2025
pulisher
Feb 02, 2025

Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL

Jan 30, 2025
pulisher
Jan 28, 2025

Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL

Jan 28, 2025
pulisher
Jan 23, 2025

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St

Jan 23, 2025
pulisher
Jan 17, 2025

Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL

Jan 17, 2025
pulisher
Jan 16, 2025

Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat

Jan 16, 2025
pulisher
Jan 14, 2025

Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL

Jan 14, 2025
pulisher
Jan 14, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Immuneering reports progress in pancreatic cancer trial - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider

Jan 13, 2025
pulisher
Jan 12, 2025

Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jan 12, 2025
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$306.27
price up icon 0.67%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
Kapitalisierung:     |  Volumen (24h):